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Abstract. 
 
The multifunctional ADP-ribosyl cyclase, 
CD38, catalyzes the cyclization of NAD
 
1
 
 to cyclic 
ADP-ribose (cADPr). The latter gates Ca
 
2
 
1
 
 release 
through microsomal membrane-resident ryanodine re-
ceptors (RyRs). We ﬁrst cloned and sequenced full-
length CD38 cDNA from a rabbit osteoclast cDNA li-
brary. The predicted amino acid sequence displayed 59, 
59, and 50% similarity, respectively, to the mouse, rat, 
and human CD38. In situ RT-PCR revealed intense cy-
toplasmic staining of osteoclasts, conﬁrming CD38 
mRNA expression. Both confocal microscopy and 
Western blotting conﬁrmed the plasma membrane lo-
calization of the CD38 protein. The ADP-ribosyl cy-
clase activity of osteoclastic CD38 was next demon-
strated by its ability to cyclize the NAD
 
1
 
 surrogate, 
NGD
 
1
 
, to its ﬂuorescent derivative cGDP-ribose. We 
then examined the effects of CD38 on osteoclast func-
tion. CD38 activation by an agonist antibody (A10) in 
the presence of substrate (NAD
 
1
 
) triggered a cytosolic 
Ca
 
2
 
1
 
 signal. Both ryanodine receptor modulators, ryan-
odine, and caffeine, markedly attenuated this cytosolic 
Ca
 
2
 
1
 
 change. Furthermore, the anti-CD38 agonist anti-
body expectedly inhibited bone resorption in the pit as-
say and elevated interleukin-6 (IL-6) secretion. IL-6, in 
turn, enhanced CD38 mRNA expression. Taken to-
gether, the results provide compelling evidence for a 
new role for CD38/ADP-ribosyl cyclase in the control 
of bone resorption, most likely exerted via cADPr.
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2
 
1
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C
 
D38/ADP-ribosyl cyclase is a key cellular enzyme
that catalyses the cyclization of the intermedi-
ary metabolite, nicotinamide adenine dinucleotide
 
(NAD
 
1
 
), to the putative second messenger, cyclic ADP-
ribose (cADPr)
 
1
 
. The latter activates Ca
 
2
 
1
 
 release from
RyR-gated Ca
 
2
 
1
 
 stores (Lee et al., 1994; DeFlora et al.,
1998). CD38 is widely distributed in hemopoietic cells, in-
cluding B and T lymphocytes, thymocytes, plasma cells,
macrophages, and erythrocytes, as well as in kidney, car-
diac, pancreatic, brain, spleen, lung, and liver cells (Mala-
vasi et al., 1992; Lee et al., 1996, 1997; Shubinski and
Schlesinger, 1997; Fernandez et al., 1998). Structurally,
CD38 is a monomeric, 46-kD, type II glycoprotein with a
short NH
 
2
 
-terminal cytoplasmic tail, a single membrane-
spanning region, and a long extracellular COOH-terminal
catalytic domain (Lee et al., 1994). The cDNAs encoding
human, mouse, and rat CD38 have been cloned. The de-
duced murine and rat CD38 sequences display 
 
z
 
75% ho-
mology with the human sequence (Harada et al., 1993;
Mehta et al., 1996; Ferrero and Malavasi, 1997).
Apart from being an ADP-ribosyl cyclase, CD38 can
function as a NAD
 
1
 
 glycohydrolase and an ADPr hydro-
lase (Lee et al., 1994; Berthelier et al., 1998). Intracellu-
larly generated cADPr is thought to play the role of a cel-
 
lular second messenger (for review, see Lee, 1996; Guse
et al., 1999). It is also considered a receptor for CD31 in B
and T lymphocytes (Deaglio et al., 1998; Horenstein et al.,
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1998). There is further evidence that plasma membrane
CD38 internalizes upon binding to monoclonal antibodies
(Funaro et al., 1998) and NAD
 
1
 
 (Zocchi et al., 1999). The
latter would yield intracellular cADPr that could poten-
tially activate microsomal membrane RyRs (Zocchi et al.,
1999). Also of note is that NAD
 
1
 
, being an intermediary
metabolite, could couple a cell’s metabolic activity to its
Ca
 
2
 
1
 
 level via the CD38/cADPr pathway.
It is now well established that the osteoclast, a cell that is
unique in its ability to resorb bone, can monitor changes in
its ambient Ca
 
2
 
1
 
 level by means of a Ca
 
2
 
1
 
 sensor (Malgar-
oli et al., 1989; Zaidi et al., 1989, 1993; Moonga et al.,
1990). A high extracellular Ca
 
2
 
1
 
, through a rise in cytoso-
lic Ca
 
2
 
1
 
, triggers dramatic osteoclast retraction, and in the
longer term, a marked inhibition of acid secretion, enzyme
release, and bone resorption (Malgaroli et al., 1989; Zaidi
et al., 1989; Datta et al., 1990; Miyauchi et al., 1990;
Moonga et al., 1990). We believe that a type 2 ryanodine
receptor (RyR-2), positioned uniquely in the osteoclast
plasma membrane, functions as a Ca
 
2
 
1
 
 channel, and possi-
bly a Ca
 
2
 
1
 
 sensor (Zaidi et al., 1995). Ordinarily, RyRs are
located in microsomal membranes and gate Ca
 
2
 
1
 
 release
in response to both Ca
 
2
 
1
 
 and cADPr.
Ca
 
2
 
1
 
 sensing in the osteoclast is regulated by several sys-
temic and local factors, namely calcitonin, interleukin-6
(IL-6), ambient pH, and membrane potential (Zaidi et al.,
1996; Adebanjo et al., 1994, 1998; Shankar et al., 1995).
We have shown recently that IL-6 attenuates the inhibi-
tory effect of Ca
 
2
 
1
 
 on the osteoclast (Adebanjo et al.,
1998). Ca
 
2
 
1
 
 in turn enhances IL-6 secretion, possibly as
part of a feedback signal to maintain resorption even in
the face of a rising Ca
 
2
 
1
 
 (Adebanjo et al., 1998). Of note is
that, during resorption, an osteoclast’s metabolic require-
ments and, hence, its NAD
 
1
 
 levels, are likely to increase
dramatically because of active proton and enzyme secre-
tion.
This study examines whether CD38/ADP ribosyl cyclase
has a new role in the regulation of osteoclastic bone re-
sorption. We first report the cloning and sequencing of
cDNA encoding a novel CD38 homologue. Furthermore,
we demonstrate that CD38 mRNA is expressed in the os-
teoclast; that immunoreactive CD38 is localized to the
cell’s plasma membrane; that the enzyme displays ADP ri-
bosyl cyclase activity in the NGD
 
1
 
®
 
cGDPr assay; that,
when activated, CD38 triggers a cytosolic Ca
 
2
 
1
 
 signal
through ryanodine receptor activation; and that the CD38-
induced Ca
 
2
 
1
 
 signal is associated with resorption inhibi-
tion and IL-6 release. We postulate that NAD
 
1
 
 couples an
osteoclast’s metabolic activity to its resorptive function us-
ing CD38 and cADPr as the sensor and signal, respec-
tively.
 
Materials and Methods
 
Osteoclast Cultures
 
Long bones obtained from neonatal Wistar rats killed by decapitation
were curetted into Hepes-buffered Medium 199 containing Hank’s salts
(GIBCO-BRL) and heat-inactivated fetal bovine serum (FBS, 5% vol/vol;
Sigma Chemical Co.) (M199-H). The resulting suspension was dispersed
onto devitalized cortical bone slices or 22-mm, 0-grade, glass coverslips
(Libro/ICN). Osteoclasts attached to the respective substrate within 15
min (37
 
8
 
C) and contaminating cells were removed by gentle rinsing. Os-
 
teoclasts were identified readily by their large size, multinuclearity, com-
plex morphology, densely ruffling edges, and response to calcitonin (Zaidi
et al., 1992).
Purified rabbit osteoclasts were prepared by the method of Kakudo et al.
(1996) from unfractionated bone cells obtained according to the proce-
dure described by Tezuka et al. (1992). In brief, cell suspensions obtained
from minced long bones of 10-d-old rabbits (Japan White; Saitama Exper-
imental Animal Supply Co.) were agitated by vortexing and plated in 10-cm
tissue culture dishes (Becton Dickinson) coated with 24% collagen gel
(Nitta Gelatin Co.). After a 3-h incubation, adherent non-osteoclasts were
removed from the collagen gel by sequential treatment with pronase E
(0.001% wt/vol) and collagenase (0.01%, wt/vol; Wako Pure Chemical In-
dustries). The remaining osteoclasts were then collected by 0.1% (wt/vol)
collagenase solution treatment and replated. When these cell suspensions
were seeded onto tissue culture dishes, osteoclasts attached and spread
out. The purity of the osteoclast preparation was judged before mem-
brane isolation by staining for an osteoclast-specific marker, tartrate-resis-
tant acid phosphatase (TRAP) using a leukocyte acid phosphatase kit
(Sigma). In line with previous experiments of Kameda et al. (1997), we
found that the purity of TRAP-positive multinucleated cells (
 
.
 
3 nuclei)
was 
 
.
 
99%. These cells have been shown to resorb bone and express spe-
cific osteoclast markers, cathepsin K, and calcitonin receptors (Takeda
et al., 1992; Kameda et al., 1997, 1998).
 
Isolation and Sequencing of CD38 cDNA Clone from a 
Rabbit Osteoclast cDNA Library
 
A rabbit osteoclast cDNA library containing 1 
 
3
 
 10
 
10
 
 independent clones
was used for PCR amplification (Tezuka et al., 1992; Kameda et al., 1998).
Two oligonucleotide primers were designed from the known rat CD38
cDNA sequence (these data are available from GenBank/EMBL/DDBJ
under accession number D29646): forward primer, 5
 
9
 
-CCTGTTGCTGT-
GTTCTGGA-3
 
9
 
 (569–588), and reverse primer, 5
 
9
 
-GGTCGGTAGT-
TATCCTGG C-3
 
9
 
 (861–843) (GIBCO-BRL). The coding region of rabbit
CD38 cDNA fragment was then amplified by PCR. In brief, the standard
reaction mixture (50 
 
m
 
l) contained: 0.1 
 
m
 
l of rabbit osteoclast cDNA li-
brary, 1 
 
m
 
l of each oligonucleotide (50 
 
m
 
l), and 1 
 
m
 
l (5 U) of AmpliTaq
(Promega Corp.). The GeneAmp PCR System 2400 (Perkin Elmer) was
programmed as follows: a 5-min cycle at 95
 
8
 
C, then 40, 1-min cycles at 95,
55, and 72
 
8
 
C. The PCR products were separated by agarose gel electro-
phoresis. A 
 
z
 
300-bp DNA fragment was isolated from excised gel slices
using a QIAquick Gel Extraction Kit (QIAGEN Inc.) and ligated into
EcoRV-cut pBluescript II SK (
 
1
 
/
 
2
 
) vector (Stratagene Ltd.) to produce
the plasmid, pBS-CD38, which was then transformed into competent
DH5
 
a
 
 cells. 293 bp of pBS-CD38 insert was confirmed through the DNA
Sequencing Facility at the University of Pennsylvania.
To obtain the full-length CD38 cDNA, the 293-bp CD38 coding region
DNA fragment was used as probe to screen our osteoclast cDNA library
(by a method described by Sambrook, 1989). For this, the probe was la-
beled with 
 
a
 
-[
 
32
 
P]CTP (3,000 Ci/mmol) (NEN™ Life Science Products
Inc.) using the 
 
Red
 
prime Random Prime Labeling Kit (Amersham Phar-
macia Biotech Inc.). Duplicate filters, which covered 1
 
 3 
 
10
 
7
 
 independent
clones, were then hybridized overnight at 42
 
8
 
C with prehybridization solu-
tion (50% formamide, 6
 
3
 
 SSC, 5
 
3
 
 Denhardt’s, 0.5% SDS, 0.1 mg/ml de-
natured fragmented salmon sperm DNA) to which a labeled probe was
added 3 h later. After a high-strigency wash at 68
 
8
 
C for 1 h, the filters were
exposed to x-ray film with intensifying screens for 20 h at 
 
2
 
70
 
8
 
C. Positive
recombinant plaques were purified from phage plate lysates according to
the Lambda ZAP II library’s instruction manual (Stratagene). The DNA
clones were confirmed by PstI-KpnI restriction analysis and direct nucle-
otide sequencing.
 
CD38 mRNA Expression in Single Osteoclasts 
Revealed by In Situ RT-PCR Cytoimaging
 
We and others have recently applied in situ RT-PCR cytoimaging success-
fully to study IL-6 and IL-6 receptor expression in osteoblasts, osteoclasts,
and bone marrow stromal cells (Lin et al., 1997; Adebanjo et al., 1998).
We now utilize this technology to examine CD38 expression in mature rat
osteoclasts (primer sequences, as above). As a positive control, we also
examined the expression of a housekeeping gene (glyceraldehyde 3-phos-
phate dehydrogenase, GADPH, data available from GenBank/EMBL/
DDBJ under accession number M32599) and an osteoclast-specific gene
(cathepsin K, accession number AF010306). Their primer sequences were:
GAPDH, forward: 5
 
9
 
-TGAAGGTCGGTGTGAACGGATTTGGC-3
 
9 
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(51–76), reverse: 5
 
9
 
-CATGTAGGCCATGAGGTCCACCAC-3
 
9
 
 (1033–
1010); cathepsin K, forward: 5
 
9
 
-CCCAGACTCCATCGACTATCG-3
 
9
 
(345–365), reverse: 5
 
9
 
-CTGTACCCTCTGCATTTAGCTGCC-3
 
9
 
 (674–
651).
Osteoclasts were incubated on glass coverslips (22 mm, 0 grade) in Me-
dium 199 with Earle’s salts (6.6 mM Na
 
2
 
CO
 
3
 
, M199-E) for 6 h (37
 
8
 
C, 5%
humidified CO
 
2
 
, pH 7.4). In separate experiments, the cells were incu-
bated with either vehicle or IL-6 (10 ng/liter or 10 
 
m
 
g/liter). The cultures
were washed with M199-E, fixed with paraformaldehyde (4% vol/vol) in
phosphate-buffered saline (PBS) (20 min, 4
 
8
 
C), and washed twice with
cold PBS. The fixed cells were treated with 0.2 N-HCl (20 min, 20
 
8
 
C),
washed with DEPC-water (Sigma Chemical Co.), and treated with pro-
teinase-K (5 mg/liter in 10 mM Tris-HCl, pH 8, 15 min, 37
 
8
 
C) and cold
paraformaldehyde (4% vol/vol, 30 min, 4
 
8
 
C). Before being air-dried, the
cells were dehydrated by sequential 1-min immersions in graded aqueous
ethanol solutions, 70, 80, 90, and 100% (vol/vol). They were then incu-
bated overnight (37
 
8
 
C) with RNase-free DNase I (1,500 units/ml; Boeh-
ringer Mannheim) to remove genomic DNA. The DNase I was finally
washed out with DEPC-water and inactivated by heating (90
 
8
 
C, 10 min).
First-strand cDNA was synthesized by incubating cultures with RT
mixture (50 
 
m
 
l) comprising 1 mM dNTP, 0.01 M DTT, 400 nM reverse
primer (above), DEPC-water, and 14 U/ml Superscript RT II (GIBCO-
BRL) (42
 
8
 
C, 60 min). An AmpliCover disc was used to cover each sample.
The samples were then treated separately with PCR mixture (50 
 
m
 
l) com-
prising 0.2 mM dNTP, PCR buffer, 2.5 mM MgCl
 
2
 
, 0.1 U/
 
m
 
l Taq poly-
merase, 400 nM forward and reverse primers, 10 
 
m
 
M digoxigenin (DIG)-
labeled-11-dUTP (Boehringer Mannheim), and DEPC-water. Each
sample  was then covered gently with an AmpliCover disc ensuring the ab-
sence of air bubbles. The GeneAmp In situ PCR System 1000 (Perkin
Elmer) was programmed as follows. A 4-min soak at 94
 
8
 
C was followed by
40 cycles of: 94
 
8
 
C for 1 min, 55
 
8
 
C for 2 min, and 72
 
8
 
C for 3 min.
Incorporated DIG-11-dUTP in the PCR product was detected by an al-
kaline phosphatase (AP)-conjugated anti-DIG antiserum and AP sub-
strates, 4-nitroblue tetrazolium chloride (NBT) and 5-bromo-4-chloro-
3-indoyl-phosphate (BCIP) using a DIG Nucleic Acid Detection Kit
(Boehringer Mannheim) per manufacturer’s protocol. Negative controls,
in which primers were omitted, were run in parallel. Messenger RNA ex-
pressing cells stained dark purplish brown, while negative controls did not
stain.
We then performed an analysis of the staining intensity using a blinded
observer. Osteoclasts were scored on a scale from 0 to 4 (no staining to in-
tense staining, see legend to Fig. 4). The results from three experiments
were plotted as a frequency histogram. This allowed us to determine the
proportion of cells that lay in a certain intensity range. A similar analysis
has been used by us previously (Adebanjo et al., 1998) to demonstrate the
effects of Ca
 
2
 
1
 
 on IL-6 and IL-6 receptor mRNA expression. Notably,
GAPDH, a housekeeping gene, was used to control for the effects of IL-6
on CD38 expression. Also note, that, as previously, the few retracted os-
teoclasts were discarded from the analysis to prevent a biased intensity as-
sessment.
 
Antibodies
 
Dr. F. Malavasi (Torino, Italy) kindly provided the monoclonal anti-CD38
antibody, A10. A10 was raised by immunizing mice with Burkitt’s lym-
phoma Daudi cells (Malavasi et al., 1984, 1985). The antibody recognizes a
46-kD CD38 molecule on T and B lymphocytes also enhancing their acti-
vation and proliferation (hence the term, agonist) (Funaro et al., 1990).
An antagonist antibody (Sigma Chemical Co.) was also used to establish
specificity for CD38 detection in the ADP ribosyl cyclase assay. The con-
trol anti-ryanodine receptor antibody, Ab
 
34
 
, was raised against a cytosolic
calmodulin-binding RyR epitope. Therefore, it does not stain nonperme-
abilized osteoclasts (Zaidi et al., 1995).
 
Immunocytochemistry and Confocal
Microscopic Analysis
 
Osteoclasts were incubated with normal goat serum (in 10 mM PBS, 1:10,
pH,
 
 
 
7.4, 15 min) in multiwell dishes and washed with HBSS (GIBCO-
BRL). The cells were either incubated without antibody, or with non-
immune mouse IgG, Ab
 
34
 
 (anti-RyR antibody) (all controls), or A10
(anti-CD38 antibody) (in M199-H, 1:100). In the same experiment, CD38-
negative fibroblasts were also incubated with the same antibodies. The
coverslips were rinsed gently with HBSS, drained, reincubated with
goat anti–mouse FITC (Sigma Chemical Co.; 1:100, in HBSS, 60 min),
 
washed gently, and finally, drained. The number of fluorescent osteoclasts
was first determined in a laser confocal scanning microscope, at 
 
l
 
ex
 
 
 
5
 
495 nm and 
 
l
 
em
 
 
 
5 
 
525 nm (Leica Inc.). To localize staining to the osteo-
clast membrane, 1-
 
m
 
m-thick optical sections were obtained in the cell’s
coronal plane in selected experiments. Finally, trypan blue (1 mM, 961
Da; Sigma Chemical Co.) was applied to exclude membrane damage that
could allow antibody access into the cell.
 
Membrane Isolation and Western Blot Analysis
 
For isolation of plasma membranes, cells were first scraped and homoge-
nized in TKM solution (50 mM Tris-HCl, pH 7.5, 25 mM KCl and 5 mM
MgCl
 
2
 
) supplemented with 0.25 mM sucrose. The homogenate was centri-
fuged (3,000 
 
g
 
, 10 min), the pellet resuspended in sucrose (70% wt/vol),
and then rehomogenized (12 strokes) with a glass/Teflon homogenizer.
The sucrose solution was then layered as follows: the homogenate was
overlaid with 12 ml of 48% (wt/vol) sucrose, followed by 6 ml of 42% (wt/
vol) sucrose. This was then centrifuged at 27,700 rpm for 70 min in a SW-
28 swinging bucket rotor. The plasma membrane fraction banding at the
interface of 70%/48% sucrose was collected and suspended in 70% (wt/
vol) sucrose solution. The entire process was repeated twice to purify the
plasma membranes.
SDS-PAGE was performed using 12% separating and 4% stacking
polyacrylamide gels using a minigel system (BioRad Laboratories).
Plasma membranes prepared from osteoclasts and osteoblasts (30 
 
m
 
g pro-
tein) were heated for 5 min at 95
 
8
 
C in Laemelli’s sample buffer (2% SDS,
2% b-mercaptoethanol, 10% vol/vol glycerol and 50 mg/liter bromophe-
nol blue in 0.1 M Tris-HCl buffer, pH 6.8). Electrophoresis was performed
at 20 mAmps per gel. The proteins thus resolved were stained with Coo-
massie Brilliant Blue (Sigma Chemical Co.) or transferred electrophoreti-
cally onto OPTITRAN-supported nitrocellulose membrane (Schleicher
and Schuell) at 158C for 1 h at 100 volts. The membranes were blocked
with Tween 20 (0.3% vol/vol) in PBS at 208C and incubated with the anti-
CD38 antibody (1:3,000) (Sigma Chemical Co.). After rinsing, the blot
was incubated for 1 h with HRP-conjugated anti–mouse antibody. The
blot was developed using Pierce SuperSignal Ultra Chemiluminescence
Kit, per manufacturer’s instructions.
ADP-Ribosyl Cyclase (NGD1®cGDPr) Assay
ADP-ribosyl cyclase activity was measured in osteoclast plasma mem-
branes isolated as above. We measured the cyclization of the NAD1 sur-
rogate, NGD1, to its fluorescent derivative, cGDPr. Plasma membranes
(25 mg) were incubated, for 20 min at 378C, in 20 mM Tris-HCl (pH 7.4)
with 100 mM NGD1. The reaction was stopped with 5 ml of 100% (vol/vol)
trichloroacetic acid. Fluorescence in the supernatant was measured using
a high-sensitivity spectrofluorometer (lex 5 300 nm; lem 5 410 nm). The
amount of cGDPr formed was plotted as mean 6 SD in nmol/ml/mg pro-
tein. To establish specificity of the assay, we incubated membranes in with
anti-CD38 antibody (1:1,000; Sigma Chemical Co.) and NAD1 (400 mM).
Mouse IgG5 was used as control.
Measurement of Cytosolic Ca21 in Single Osteoclasts
Glass coverslips containing freshly isolated osteoclasts were incubated in
serum-free medium (30 min, 378C) with 10 mM fura 2/AM (Molecular
Probes), then washed in M199-H and transferred to a Perspex bath posi-
tioned on the microspectrofluorometer stage. The latter was previously
constructed from an inverted microscope (Diaphot; Nikon) (Shankar et al.,
1992). Prewarmed test solutions of the anti-CD38 antibodies (A10, agonist
and antagonist; Sigma Chemical Co.) (1:500), NAD1 (0.5, 1, or 10 mM), ry-
anodine (5 mM), caffeine (250 mM and 1 mM), or thapsigargin (4 mM)
were applied in various protocols, as described in Results. The cells were
exposed alternatively to excitation ls of 340 or 380 nm. The emitted fluo-
rescence was deflected through a 400-nm dichroic mirror and subse-
quently filtered at 510 nm. The signal was converted to 25 ns, 5V transis-
tor-transistor-logic (TTL) pulses in a photomultiplier tube (PM28B;
Thorn EMI). The resulting pulses were counted by a dual photon counter
(Newcastle Photometrics) and recorded every second to give a ratio of
emitted intensities at excitation ls of 340 and 380 nm, F340/F380.
The cytosolic Ca21 measuring system was calibrated using an estab-
lished protocol for intracellular calibration (Shankar et al., 1993). In brief,
fura 2–loaded osteoclasts were bathed in Ca21-free, EGTA-containing so-
lution containing 130 mM NaCl, 5 mM KCl, 5 mM glucose, 0.8 mM MgCl2,
10 mM Hepes, and 0.1 mM EGTA. 5 mM ionomycin was first applied to
obtain the minimum ratio due to lowest cytosolic Ca21 (Rmin) and theThe Journal of Cell Biology, Volume 146, 1999 1164
maximum fluorescence intensity at 380 nm (Fmax). 1 mM CaCl2 was then
applied with 5 mM ionomycin to obtain values of the maximum ratio due
to an elevated cytosolic Ca21 (Rmax) and the minimum fluorescence inten-
sity at 380 nm (Fmin). The dissociation constant Kd for Ca21 and fura 2 is
224 nM (208C, 0.1 M, pH 6.85). The values were substituted into the equa-
tion: [Ca21]  5  Kd 3 [(R 2 Rmin)/(Rmax 2 R)] 3 [(Fmax/Fmin)]. Mean
changes (D) in the cytosolic Ca21 concentration ([Ca21]) were then calcu-
lated by subtracting peak from basal cytosolic [Ca21]. Statistical compari-
sons of cytosolic D [Ca21] were made by Analysis of Variance (ANOVA)
with Bonferroni’s Correction for Inequality.
Bone Resorption Assay
Bone resorption was measured using the pit assay (Boyde et al., 1984;
Chambers et al., 1984; Dempster et al., 1987). In brief, the bones from 24-
to 48-h-old rats were sliced in 3.5 ml M199-H, and the resulting cell sus-
pension was settled onto devitalized cortical bone slices (4 mm 3 4 mm)
for 30 min. After the removal of nonadherent cells by gentle rinsing, the
slices were transferred to a multiwell dish containing M199-E (with 10%
FBS vol/vol). Either vehicle or anti-CD38 antibody (1:500 or 1:5,000) were
applied together with 1 mM NAD1.
The slices were incubated for 24 h in humidified CO2 (5%) (pH 6.9), af-
ter which they were fixed with glutaraldehyde (10% vol/vol) and stained
for the presence of tartrate-resistant acid phosphatase (TRAP) using a kit
(Kit 386A; Sigma Chemical Co.). The number of osteoclasts with two or
more nuclei was determined on each slice using a light microscope (Olym-
pus). The cells were removed by treating the slices with NaOCl (5 min),
and the slices rinsed with distilled water followed by acetone, and then air-
dried. The slices were stained subsequently with toluidine blue (1% vol/
vol, in 1% wt/vol borate, 5 min). The number of resorption pits was deter-
mined on each slice by light microscopy. Notably, each experiment was
performed with osteoclasts obtained from three animals with five or six
bone slices per treatment. The number of pits or osteoclasts per bone slice
was expressed as a mean 6 SEM. Student’s unpaired t test was used to an-
alyze the effect of treatment, which was considered significant at P , 0.05.
Supernatant IL-6 Measurements by ELISA
Osteoclasts on coverslips were bathed in a multiwell dish containing 500
ml M199-E (with 10% FBS vol/vol) for 6 h in the presence of either vehi-
cle or anti-CD38 antibody (1:500) and NAD1 (1 mM). The culture me-
dium was removed and its IL-6 level was measured with an ELISA kit
(M6000; R&D). In brief, 96-well plates coated with a polyclonal anti–
mouse IL-6 antiserum were used to accommodate 50 ml of assay diluent
(buffered protein) and 50 ml of standard, control, or sample. After incuba-
tion (208C, 2 h), the wells were aspirated, washed repeatedly, and loaded
with 100 ml horseradish peroxidase–conjugated anti–IL-6 antibody. After
a further incubation (208C, 2 h), 100 ml of substrate solution containing
H2O2 and tetramethylbenzidine, was added to each well. Finally, a fur-
ther incubation (30 min) was followed by the addition of 100 ml of dilute
HCl to stop the reaction. The optical density of each sample was mea-
sured at 450 nm on a microplate reader (BioRad). IL-6 was estimated
from the standard curve in triplicate experiments and represented as
mean 6 SEM. Differences between control and treatment were assessed
by the Student’s unpaired t test.
Results
Isolation and DNA Sequence Analysis of a 2.8-kb 
Rabbit Osteoclast CD38 cDNA
To obtain full-length CD38 cDNA clones, a rabbit osteo-
clast cDNA library was screened. A 293-bp CD38 cDNA
coding region DNA fragment was initially cloned and used
as probe. A single positive cDNA clone was identified af-
ter screening 1 3 107 independent phage recombinants;
this contained a 2.8-kb EcoRI-XhoI insert in the plasmid
pBluescript-SK (termed SL385). The sequence of the full-
length SL385 CD38 insert was obtained. Sequence analysis
confirmed the presence of the CD38 coding sequence and
extended into 39-untranslated region (Fig. 1). The osteo-
clast CD38 cDNA sequence was 71, 69, and 66% similar
to corresponding full-length CD38 cDNA sequences of
mouse, rat, and human CD38 (obtained from the Gen-
Bank database) (Fig. 1). No significant homology was
found, however, between the sequence of the insert and
any other sequence in the GenBank database. Fig. 2 shows
the predicted amino acid sequence of the full-length rabbit
osteoclastic CD38. There was a 59, 59, and 50% similarity
between this sequence and that of mouse, rat, and human
CD38 (GenBank), respectively. The relative sequence di-
vergence suggests that the amplified DNA product codes
for a yet uncharacterized member of the CD38 family of
cyclases.
CD38 mRNA in Single Osteoclasts Demonstrated by In 
Situ RT-bPCR Cytoimaging
CD38 mRNA expression in isolated single osteoclasts
was investigated by in situ RT-PCR cytoimaging using
the same primers as used for PCR cloning (above). Fig. 3
shows light micrographs of histostained osteoclasts after
RT-PCR. Panel i shows an unstained osteoclast (nega-
tive controls) in an experiment in which primers were
omitted from the reaction mixture. Panels ii and iii show
osteoclasts in which the intense bluish-brown staining
represents, respectively, mRNA expression for cathep-
sin K (cell-specific positive control) or GAPDH (house-
keeping gene). Panels iv to vi show intense CD38
mRNA histostaining in osteoclasts that were either incu-
bated with vehicle (iv), 10 ng/liter IL-6 (v), or 10 mg/liter
IL-6 (vi).
Fig. 4 shows a semi-quantitative analysis of staining in-
tensity using a method modified from that reported by
Adebanjo et al. (1998). Osteoclasts staining for CD38
mRNA were thus assessed by a blinded observer who as-
signed an intensity level to the staining as a number be-
tween 0 and 4 (no staining to intense staining). Three ex-
periments were pooled to derive frequency histograms
relating the number of cells to their assigned intensity
score. Osteoclasts that underwent in situ RT-PCR without
added primers (control) showed a skewed distribution to
the left (i, n 5 26 cells). Cells incubated with primers, but
without treatment for 6 h with IL-6 (ii, n 5 49 cells) or
those treated with 10 ng/liter IL-6 (iii, n 5 53 cells), showed
a normal (Gaussian) distribution of their assigned scores.
The data became significantly skewed (P , 0.05) to the
right when osteoclasts were treated with 10 mg/liter IL-6
(iv, n 5 29 cells). In contrast, the expression of mRNA for
GAPDH, the housekeeping gene, followed a similar distri-
bution in all three experimental sets, namely no treatment,
10 ng/liter IL-6, and 10 mg/liter IL-6 (not shown). Taken
together, the results showed that a much larger proportion
of cells stained intensely with 10 mg/liter IL-6 compared
with 10 ng/liter IL-6, suggesting that the former concentra-
tion of IL-6 might enhance CD38 mRNA levels. As in our
earlier study (Adebanjo et al., 1998), we must emphasize
that the results are semi-quantitative at best, due not only
to the inherent pitfalls of the in situ RT-PCR technique,
but also because the cells may undergo slight margin re-
traction resulting in scoring artifacts. Again, as before, we
have excluded obviously retracted cells, as in these cells,
staining is likely to appear more intense due to cytoplas-
mic condensation.Sun et al. CD38 and cADPr in Osteoclast Regulation 1165
Figure 1. Nucleotide sequence of rabbit osteoclast CD38 cDNA compared with the known mouse, rat, and human sequences, as shown.
The respective sequences were 59, 59, and 50% homologous with the rabbit CD38 sequence. The 59 and 39-untranslated regions (21 to
–76 bp and 898 to 2,798 bp, respectively) are also shown. The start and stop codons are indicated in bold. Gaps are introduced to maxi-
mize homology.The Journal of Cell Biology, Volume 146, 1999 1166
CD38 Localization to the Osteoclast Plasma Membrane
We next examined whether our highly specific anti-CD38
antibody, A10, bound to the surface of intact live osteo-
clasts. This agonist antibody has previously been shown to
bind to, and activate, the CD38 antigen in several systems
(Funaro et al., 1990). Fig. 5 (B–D) shows confocal micro-
scopic images taken at 1-mm intervals in the coronal plane
of CD38-positive osteoclasts. Intense, strictly peripheral,
immunostaining was visualized distinctly reminiscent of
plasma membrane staining. Notably, CD38-negative fibro-
blasts were found not to stain with the antibody (not
shown). Also of note is that every one of the z20 osteo-
clasts examined in each different experiment showed posi-
tive staining. Furthermore, all cells remained negative for
trypan blue, excluding membrane damage that would oth-
erwise permit antibody access into the cytosol.
Control experiments were performed by (a) not includ-
ing the anti-CD38 antibody (not shown); (b) using preim-
mune mouse IgG instead of the antibody (not shown); (c)
using an irrelevant anti-ryanodine receptor antibody, Ab34
(Fig. 5 A). That osteoclasts did not stain with any such
treatment provided clear evidence for specificity. Note
that Ab34 was raised against a cytosolic calmodulin-bind-
ing sequence of the RyR, and hence, is known not to stain
the surface of nonpermeabilized osteoclasts (Zaidi et al.,
1995). A negative result with the latter antibody further at-
tests to an intact plasma membrane.
We further confirmed that the CD38 protein was pres-
ent in isolated osteoclast plasma membranes by Western
blotting using a different antagonist anti-CD38 antibody
(Sigma Chemical Co.). A z46 kD band was observed
when plasma membranes purified by sucrose gradient cen-
trifugation were electrophoresed and immunoblotted (Fig.
6). A further, significantly weaker, band of a smaller mo-
lecular weight (z39 kD) was also seen; this may represent
a degradation product, but we are unclear of its identity.
The latter band was not obvious when post-nuclear mem-
branes from osteoblastic MC3T3-E1 cells were similarly
immunoblotted. Note that the purity of the osteoclastic
preparations was .99% based on TRAP staining (see Ma-
terials and Methods).
ADP Ribosyl Cyclase Activity in Osteoclast Plasma 
Membranes in the NGD1®cGDPr Assay
CD38 is not only an ADP-ribosyl cyclase that converts
NAD1 to cADPr, but is also an ADP hydrolase convert-
ing active cADPr to inactive ADP-ribose. It is difficult to
separate the two reactions that proceed simultaneously.
We have therefore used an assay that monitors cyclization
of NGD1 to cGDPr, a nonhydrolyzable cADPr surrogate.
Thus, the rate of cGDPr formation, in the absence of its
breakdown, will more accurately reflect the ADP-ribosyl
cyclase activity of CD38. Furthermore, cGDPr is a fluores-
cent compound that can be quantitated by fluorimetry.
We found that osteoclast plasma membranes synthesized
cGDPr at a rate of 4.3 nmoles/min/mg protein (Fig. 7). The
anti-CD38 antagonist antibody (Sigma Chemical Co.) in-
hibited cGDPr formation significantly, thus attributing the
observed ADP ribosyl cyclase activity to CD38. Enzyme
activity was also inhibited significantly by addition of
NAD1 (400 mM), indicating a possible competition be-
tween the two nucleotides. Similar results were obtained
from postnuclear membranes prepared MC3T3-E1 osteo-
blasts (not shown).
Cytosolic Ca21 Signals Triggered through CD38 
Activation and cADPr Generation
Having established the presence of CD38 in the osteoclast
plasma membrane, we next investigated the effects of its
activation by the agonist anti-CD38 antibody. Thus, we
measured changes in cytosolic [Ca21] in response to appli-
cation of NAD1 (substrate) in the presence of the agonist
antibody. Expectedly, only in the presence of the antibody
(1:500), did 1 mM NAD1 trigger a cytosolic [Ca21] eleva-
tion (Fig. 8 A). This result was consistent with an activated
CD38/ADP-ribosyl cyclase that catalyses cADPr genera-
tion from NAD1. In separate experiments, the anti-CD38
antibody itself, in the absence of NAD1, did not elevate
cytosolic [Ca21], indicating that the substrate, NAD1, was
necessary for CD38-induced Ca21 signaling (not shown).
Finally, 1 mM NAD1 failed to trigger a cytosolic Ca21 sig-
nal in the presence of the control anti-RyR antibody, Ab34,
further confirming response specificity.
At higher, 10 mM, NAD1 concentrations, a marked ele-
vation in cytosolic [Ca21] was noted even in the absence of
the antibody (Fig. 8 A). This response was significantly
different (P  5  0.013) to the control response (1 mM
NAD1 alone), but did not differ significantly (P 5 0.22)
Figure 2. Predicted amino acid sequence of rabbit osteoclast
CD38 compared with the known mouse, rat, and human se-
quences, as shown. The respective sequences were 69, 61, and
58% homologous with the rabbit CD38 sequence. Gaps are intro-
duced to maximize homology. Asterisks indicate across-species
identity of residues.Sun et al. CD38 and cADPr in Osteoclast Regulation 1167
from the response triggered by 1 mM NAD1 with anti-
body (Fig. 8 A).
We further demonstrated CD38-specificity of the NAD1-
induced cytosolic Ca21 response by preincubating osteo-
clasts with the anti-CD38 antagonist antibody (Sigma
Chemical Co.) before application of 10 mM NAD1. The
antagonist antibody attenuated the magnitude of the cyto-
solic Ca21 response significantly (Fig. 8 C).
To determine whether NAD1 triggered the release of
Ca21 from intracellular stores, we carried out experiments
with 10 mM NAD1 in the presence or absence of 2 mM
EGTA (to chelate extracellular Ca21 to near-nanomolar
levels) or thapsigargin (a microsomal membrane Ca21-
ATPase inhibitor that is known to deplete intracellular
Ca21 stores). The response to 10 mM NAD1 in Ca21-free,
EGTA-containing medium remained unchanged com-
pared with that to 10 mM NAD1 in 1.25 mM Ca21 (P 5
0.335). Furthermore, Fig. 8 B shows that when cells were
treated with 4 mM thapsigargin, there was a significant at-
tenuation of the cytosolic Ca21 response to 10 mM NAD1.
However, it is notable that thapsigargin did not completely
abolish the cytosolic Ca21 response to NAD1 suggesting
that the Ca21 signal was not completely dependent upon
the fullness of intracellular Ca21 stores. Taken together,
the results suggested that NAD1 primarily triggered the
release of Ca21 from intracellular Ca21 stores, although
Ca21 influx may also play a role.
We next attempted to test the hypothesis that NAD1-
induced cADPr generation resulted in the activation of
intracellular ryanodine receptors. For this, we exam-
ined  whether the known cell permeant ryanodine receptor
Figure 3. Histostained osteoclasts following
in situ  RT-PCR for detection of CD38
mRNA. i shows a negative control from a
representative experiment i.e., without
added primer. ii and iii represent histostain-
ing for cathepsin K (Cath K) (cell-spe-
cific positive control) and glyceraldehyde-
3-phosphate dehydrogenase (GAPDH)
mRNA (housekeeping gene). Panels iv to vi
show CD38 mRNA staining in osteoclasts
incubated either in vehicle (iv) or with 10
ng/liter IL6 (v) or 10 mg/liter IL6 (vi). For
details and primer sequences refer to Mate-
rials and Methods.
Figure 4. Semiquantitative representation in frequency histo-
grams of intensity score after in situ RT-PCR for CD38 mRNA
in osteoclasts incubated either without primer (i) or with CD38
primers without IL-6 treatment (ii) or with IL-6 treatment (10 ng/l,
iii, or 10 mg/l, iv). Staining intensity was graded as described in
Materials and Methods by an independent blinded observer who
scored the intensity from zero (no staining) to 4 (intense staining)
in three experiments. The data were analyzed statistically for
skewness and shifts were considered significant if P , 0.05.The Journal of Cell Biology, Volume 146, 1999 1168
modulators, ryanodine and caffeine, inhibited the re-
sponse to applied NAD1. Both ryanodine (5 mM) and caf-
feine (250 mM and 1 mM) significantly inhibited the cyto-
solic Ca21 response to NAD1 (P values, see legend to Fig.
8). Taken together, the results suggest that RyR-gated
Ca21 stores were being emptied in response to NAD1, im-
plicating, though not proving, a direct role of cADPr as a
second messenger. This is consistent with our direct dem-
onstration of cADPr-forming, ADP-ribosyl cyclase activ-
ity in the osteoclast plasma membrane as assessed by the
NGD®cGDPr assay (Fig. 7). It should be emphasized
that thapsigargin, ryanodine, and caffeine have all been
used as tools to understand the mechanism of NAD1-
induced Ca21 signaling, and in view of their other cellular
actions would not be expected to reverse the effect of
NAD1 on bone resorption and IL-6 release.
Inhibition of Bone Resorption and Enhancement of IL-6 
Release by CD38 Activation
We have shown that while a cytosolic Ca21 change triggers
resorption inhibition, it elevates IL-6 synthesis and release
(Zaidi et al., 1989, Moonga et al., 1990, Adebanjo et al.,
1998). Our goal, therefore, was to examine the effect of
CD38 activation by NAD1 (in the presence of its agonist
antibody, A10) on bone resorption and IL-6 release. In the
presence of A10, at either dilutions (1:5,000 or 1:500), 1 mM
NAD1 inhibited osteoclastic bone resorption significantly
(P 5 0.034 and P 5 0.025, respectively, compared with ve-
hicle-treated cells) (Fig. 9 a). Expectedly, osteoclast num-
ber per slice did not change significantly (P . 0.05 for ei-
ther antibody dilution) (Fig. 9 b), excluding an effect of
the antibody on osteoclast formation or demise. In sepa-
rate experiments, the 1 mM NAD1 (in the presence of
A10, 1:500), caused a dramatic and highly significant
threefold elevation (P , 0.001) of IL-6 release (Fig. 9 c).
Taken together, the results appear consistent with the par-
adoxical effects of Ca21 on bone resorption and IL-6 re-
lease (Moonga et al., 1990; Adebanjo et al., 1998).
Discussion
The multifunctional ectoenzyme, CD38, is known to mod-
ulate lymphocyte functions as critical as adhesion, prolif-
eration and cytokine production (Cesano et al., 1998,
Ferrero and Malavasi, 1997). It also functions as a coun-
ter-receptor for CD31, presumably facilitating cell-to-cell
communication (Deaglio et al., 1998; Horenstein et al.,
1998). It is also an ADP-ribosyl cyclase that catalyzes the
formation of cADPr from NAD1. Several reports have
suggested that the latter is a cellular second messenger,
somewhat akin to IP3 (for review: Lee, 1996; Guse et al.,
1999). We show that CD38 regulates osteoclastic bone re-
sorption via the production of cADPr. Specifically, we
show that a novel CD38 homologue is located in the rabbit
osteoclast plasma membrane; that it possesses ADP-ribo-
syl cyclase activity; that its activation results in cytosolic
Ca21 elevation through ryanodine receptor activation; and
that the cytosolic Ca21 change is accompanied, quite ex-
pectedly, by an elevation in IL-6 release and resorption in-
hibition.
Figure 5. Confocal microscopic localization of the CD38 antigen
on the osteoclast plasma membrane. Intense peripheral immu-
nofluorescent staining of osteoclasts with a highly specific agonist
anti-CD38 monoclonal antibody, A10. 1-mm-thick serial sections
in the coronal plane (B–D) are shown. Note that osteoclasts incu-
bated with no antiserum (not shown), nonimmune mouse IgG
(not shown), or an irrelevant antibody (Ab34) (A) do not stain.
For details on confocal microscopy, see Materials and Methods.
Figure 6. Western blotting after
SDS-PAGE of osteoclast plasma
membranes (OC-PM) (30 mg
protein) and osteoblast postnu-
clear membranes (OB-PNM) (50
mg protein) using an antagonist
anti-CD38 antibody (Sigma
Chemical Co.). We identified
46-kD bands with an additional
lower molecular weight band in OC-PMs. The osteoclast prepa-
rations were .99% pure as assessed by TRAP staining (see Ma-
terials and Methods).
Figure 7. ADP-ribosyl cy-
clase activity of CD38 in iso-
lated osteoclast plasma mem-
branes. The conversion of the
NAD1 surrogate, NGD1, to
the nonhydrolyzable fluores-
cent product, cyclic GDP-
ribose (cGDPr) was assessed
fluorimetrically (see Materi-
als and Methods for details).
Results are expressed as a
mean (6 SEM) cGDPr
formed in nmoles/min/mg isolated plasma membrane protein
without treatment (basal) or in the presence of nonimmune mouse
serum (IgG5) (NIMS), an antagonist anti-CD38 antibody (Ab;
Sigma Chemical Co., 1:500) or NAD1 (400 mM). The asterisks
represent significant differences compared with basal (P , 0.05).Sun et al. CD38 and cADPr in Osteoclast Regulation 1169
CD38 catalyzes the cyclization of NAD1 not only to
cADPr (Howard et al., 1993), but also to the more recently
described, dimeric ADPr (DeFlora et al., 1997a). While
the classical action of cADPr is to release Ca21 from RyR-
bearing Ca21 stores, dimeric ADPr potentiates this effect
(DeFlora et al., 1997a). In the osteoclast, we have shown
that cADPr triggers both Ca21 release and Ca21 influx
through its action, respectively, on microsomal membrane
RyRs and a uniquely positioned surface RyR-2 (Zaidi et al.,
1995; Adebanjo et al., 1996). Apart from being activated
by cADPr, the uniquely positioned osteoclast surface
RyR-2 appears also to sense changes in the cell’s ambient
Ca21 concentration during resorption (Zaidi et al., 1995).
Any rise in cytosolic Ca21 in the osteoclast triggers rapid
cell retraction, diminished enzyme release, and reduced
acid secretion, culminating finally, in the inhibition of
bone resorption (Malgaroli et al., 1989; Zaidi et al., 1989;
Datta et al., 1990; Miyauchi et al., 1990; Moonga et al.,
1990). However, an increased cytosolic Ca21 also enhances
IL-6 secretion, possibly to release an osteoclast from the
resorption inhibition induced by a high Ca21 (Adebanjo
et al., 1998).
The observed effect of CD38 activation in inhibiting
bone resorption and elevating IL-6 release thus mirrors
that of Ca21. Notably, both agents act by elevating cytoso-
lic Ca21. Interestingly, however, cADPr-induced Ca21 re-
lease also mediates the effect of CD38 in inducing other
cytokines, including IL-6, interferon-g, granulocyte-mac-
rophage colony stimulating factor (GM-CSF), and IL-10
(Ausiello et al., 1996). Cyclic ADPr also promotes secre-
tion of hormones, such as insulin from pancreatic b cells,
and cytokines from T cells (Takasawa et al., 1998; Cesano
et al., 1998). Nevertheless, it is unclear as to how these re-
leased cytokines, in turn, affect CD38 expression and
cADPr formation. We provide new evidence that IL-6 en-
hances the expression of CD38 mRNA. This appears con-
sistent with a NF-IL-6 site in the CD38 gene promoter
(Kishimoto et al., 1998). Our in situ RT-PCR results, how-
ever, must be treated with caution in view of the known
technological pitfalls and possible artifacts, which we have
tried to avoid.
The Ca21-like effects of CD38 might also be relevant
physiologically in the metabolic control of bone resorption
via NAD1. It is noteworthy that the energy requirement of
a resorbing osteoclast is high due to its active secretion of
acid and enzymes and its intense motile activity. It is
therefore possible that large amounts of NAD1 are being
generated intracellularly during resorption. Significant
amounts of this NAD1 may indeed extrude from the os-
teoclast. Indeed, Zocchi et al. (1999) have demonstrated
the existence of a saturable and bidirectional NAD1 trans-
port system in a variety of eukaryotic cells; the same could
be true for osteoclasts. Alternatively, neighboring cells un-
dergoing apoptosis may release much NAD1 (Mehta et al.,
1996). The extracellularly located catalytic domain of the
CD38/ADP-ribosyl cyclase could then sense the NAD1,
and by catalyzing its conversion to cADPr, limit further
osteoclastic resorption. Franco et al. (1998) have demon-
Figure 8. Effect of NAD1
(NAD1, concentrations as
shown) on the mean change (D)
in cytosolic [Ca21] (nM) in fura
2–loaded single osteoclasts under
various experimental conditions.
(A) Osteoclasts were preincu-
bated with either vehicle or the
anti-CD38 agonist antibody, A10
(1:500) in Medium 199-Hanks
([Ca21] 5 1.25 mM). (B) Osteo-
clasts were pretreated for sev-
eral min with the microsomal
membrane Ca21-ATPase inhibi-
tor, thapsigargin (4 mM), or with
the cell-permeant ryanodine receptor modulators, ryanodine (4 mM) or caffeine (4 mM). (C) Osteoclasts were pretreated for 15 min
with the antagonist antibody (Sigma Chemical Co.) (1:500) (Sig). Cytosolic D [Ca21] was calculated in each case by subtracting the basal
from peak cytosolic [Ca21]. Asterisks indicate P , 0.05 (n 5 6 per group).
Figure 9. Effect of the agonist anti-
CD38 antibody (A10, 1:5,000 or 1:500)
in the presence of substrate (1 mM
NAD1) on bone resorption (a, pits per
slice) and osteoclast number (b, osteo-
clasts per slice) as assessed in the pit as-
say, as well as on supernatant inter-
leukin-6 (IL-6, ng/liter) levels (c)
measured by ELISA. P values as indi-
cated (n 5 10 slices per group).The Journal of Cell Biology, Volume 146, 1999 1170
strated a role of CD38 in NAD1 sensing in HeLa cells and
human erythrocytes.
Our evidence for the production of cADPr through
NAD1 catalysis by CD38 is twofold. First, we have di-
rectly demonstrated that osteoclast plasma membranes
that are positive for CD38 immunoreactivity contain
ADP-ribosyl cyclase activity. This has been assessed using
an assay that allows for the catalytic conversion of the
NAD1 surrogate, NGD1, to its nonhydrolyzable and fluo-
rescent derivative, cGDPr. We showed that the observed
ADP-ribosyl cyclase activity could be inhibited noncompeti-
tively by an antagonist antibody to CD38, confirming di-
rectly, a role for CD38 in cGDPr formation. That NAD1
also significantly inhibited NGD1 catalysis confirmed fur-
ther that the two molecules most likely shared the same sub-
strate-binding site. cGDPr formation in osteoclast plasma
membranes thus appears truly reflective of the ADP-ribosyl
cyclase activity of CD38. Second, and in line with the above,
we have shown that NAD1 application to osteoclasts trig-
gers cytosolic Ca21 release mostly from intracellular stores
that are sensitive to inhibition by RyR modulators, ryano-
dine and caffeine. This, albeit indirect, demonstration for a
role of RyRs in NAD1-induced Ca21 release further sug-
gests a second messenger role for the generated cADPr.
Despite our molecular and biochemical demonstration
of functionally active CD38/ADP ribosyl cyclase in the os-
teoclast plasma membrane, it remains unclear how any
cADPr synthesized extracellularly could act on intracellu-
lar RyRs. Two explanations have been offered in other
models (Lund et al., 1998). First, the CD38 catalytic com-
partment may become internalized after its recognition of
substrate, thus generating cADPr intracellularly (Funaro et
al., 1998; Zocchi et al., 1998, 1999). In fact, Zocchi et al.
(1999) have shown, using endocytic vesicles, that NAD1
first internalizes through a saturable transport system in-
dependent of CD38, and once, within the vesicle, is cata-
lyzed to cADPr. The latter is then pumped out into the cy-
tosol to affect Ca21 release from RyR-gated Ca21 stores. It
has been suggested that agonist antibodies, such as A10,
may aid such internalization (Funaro et al., 1998). Indeed,
A10 is known to enhance the activation and proliferation
of B and T lymphocytes through enhanced cADPr produc-
tion (hence the term, agonist) (Funaro et al., 1990). Such a
mechanism provides one likely explanation for the syner-
gistic effects of the A10 and NAD1 on cytosolic Ca21.
An alternative possibility, however, also exists. This is
that cADPr is first generated extracellularly, and then
traverses the cell membrane to interact with intracellular
RyRs. Effects of extracellularly applied cADPr on cellular
function have been described in rat cerebellar cells (De-
Flora et al., 1996, 1997b), murine B lymphocytes (Howard
et al., 1993) and rat osteoclasts (Adebanjo et al., 1996).
Franco et al. (1998) have shown, however, using human
erythrocyte membranes and CD38-reconstituted proteo-
liposomes that CD38 is a selective transporter of cata-
lytically generated, but not exogenously added cADPr.
Indeed, CD38 internalization is currently the favored hy-
pothesis and could explain our results fully. However, the
major goal of this study has not been to probe this mecha-
nism; instead, it has been to identify a plausible role of
CD38/ADP ribosyl cyclase in the control of osteoclastic
bone resorption.
We have provided evidence that the NAD1-induced
Ca21 signal is made up of two components, Ca21 release
from RyR-gated intracellular stores, and Ca21 influx possi-
bly through the uniquely positioned plasma membrane
RyR-2. The role of ryanodine receptors has been generally
confirmed through experiments demonstrating that the cy-
tosolic Ca21 response to NAD1 is inhibited strongly by
both ryanodine and caffeine (Fig. 8). However, these ex-
periments have not allowed us to determine whether the
respective modulators block the intracellular RyRs, or the
surface RyR-2, or both. Nonetheless, we show here that
the NAD1-induced cytosolic Ca21 response is maintained
in Ca21-free, EGTA-containing medium, suggesting its de-
pendence on intracellular Ca21 release. Our experiments
with thapsigargin, a microsomal membrane Ca21-ATPase
inhibitor known to deplete intracellular Ca21 stores, ap-
pear more conclusive. These results show that thapsigargin
attenuates, but does not abolish the cytosolic Ca21 signal,
suggesting that there is a component of extracellular Ca21
influx. This, however, remains to be established.
In conclusion, we have documented a new function for
osteoclastic CD38. We believe that its activation at the os-
teoclast plasma membrane results in cytosolic Ca21 release
from RyR gated intracellular Ca21 stores via cADPr gen-
eration from NAD1. The released Ca21 then signals a re-
duction in bone resorption and a paradoxical elevation of
IL-6 release. It is therefore possible that the CD38/Ca21/
IL-6 pathway may have a critical role in coupling an osteo-
clast’s metabolic activity with its resorptive function. Our
current studies with CD382/2 mice should shed more
light on the function of CD38 in osteoclast control (Kato
et al., 1999).
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